SitemapPress Releases
Cellceutix Reports its Very Novel Anti-Cancer Agent, Kevetrin, at Dana Farber for Start of Clinical Trials 07.23.2012
Cellceutix Cancer Trial Enrollment Planned for August 2012 07.15.2012
Cellceutix Meets Manufacturers to Synthesize Psoriasis Drug Candidate for Clinical Trials 07.09.2012
Cellceutix Sets for Cancer Patient Enrollment in Clinical Trial of Pioneering p53 Cancer Drug 06.26.2012
Cellceutix Novel Anti-Cancer Drug Kevetrin(TM) Receives IRB and SRC Approvals for Clinical Trials at Harvard's Dana-Farber Cancer Institute 06.22.2012
Cellceutix Approved by FDA to Proceed With Clinical Trials on Novel Cancer Drug 06.14.2012
Cellceutix Informed by FDA That 505(b)(2) Application Would Be an Acceptable Approach for Its Psoriasis Drug 06.04.2012
Cellceutix CEO, and Advisor Jim Boeheim Interviewed by Boston Herald About New Cancer Drug; Company Provides Update on p53 Compounds From Annual ASCO Meeting 05.30.2012
Cellceutix Adds Brain Cancer to Growing List of Indications for Its Novel Cancer Drug 05.21.2012
Cellceutix Files Amended IND With FDA for Its Novel p53 "Guardian Angel" Anti-Cancer Drug 05.14.2012
Cellceutix Arranges $1 Million Financing for Clinical Trials of New Cancer Drug; IND Filing Imminent 05.07.2012
Syracuse Basketball Icon Jim Boeheim Joins Cellceutix to Fight Cancer 04.16.2012
FDA Schedules Meeting With Cellceutix on New Psoriasis Drug 04.04.2012
Cellceutix Novel Anti-Cancer Compound Kevetrin(TM) Presented at American Association for Cancer Research Annual Meeting 03.19.2012
Cellceutix Enters Into a Collaborative Agreement With Beth Israel Deaconess Medical Center for Pro-Apoptotic Function of p53 in Melanoma and Renal Cell Carcinoma 03.12.2012
Cellceutix Files Pre-IND Documentation to FDA for New Psoriasis Drug - Company Gets Started on Next Drug in Their Pipeline. 02.27.2012
Cellceutix 'Back in the Game' With cGMP Manufacturing Completed on New Cancer Drug 01.23.2012
Cellceutix Featured on Cover of Prominent Business Journal 01.17.2012
Cellceutix Anti-Cancer Drug Shown to Regulate HDAC2, a Major Therapeutic Target for Treatment of a Broad Range of Cancers. Potent Anticancer Activity Demonstrated in a Wide Range of Tumor Types as Kevetrin(TM) Targets a Histone Deacetylase 01.03.2012
Cellceutix Ushers in 2012 With Plans for Clinical Trials for Anti-Cancer and Psoriasis Drugs 12.13.2011
Cellceutix Provides Updates on IND for Cancer Drug, Initiates Collaborative Agreement With Pioneer Valley Life Sciences Institute for Mitochondrial Research 11.28.2011
Dr. Paul Marks, MD Joins Cellceutix Scientific Advisory Board; Cellceutix Files Worldwide Patents to Protect Kevetrin™ 11.04.2011
Cellceutix Files Investigational New Drug Application (IND) with FDA, Clinical Trials Planned at Dana-Farber/Harvard Cancer Center 10.25.2011
Cellceutix to File Investigational New Drug Application for Novel p53 Anti-Cancer Drug. Cellceutix Completes Clinical Protocol With Hosting Hospital; Receives Signed Forms Needed for Filing Investigational New Drug Application 10.17.2011
Cellceutix Confident as Cancer Compound Shows Activity in All Cancers Tested. Cellceutix Updates Shareholders; Answers Questions About Clinical Trials for Novel Cancer Drug. 10.10.2011
Prostate Cancer Joins Growing List of Cancers That Succumb to Cellceutix Corporation's Potent Anti-Cancer Drug Kevetrin(TM) Demonstrates Strong Anti-Tumor Activity in a Human Prostate Cancer Xenograft Model 10.03.2011
Cellceutix's Drug Discovery Is a Major Leap Forward in the Fight Against Cancer - Drug Delivery Devices Received From Hospital and Stability Studies Underway 09.26.2011
Cellceutix to Pursue 505(b)(2) Clinical Process for Psoriasis Drug. Company Releases Pictures Of Mice Studies Showing Dramatic Response To Drug 09.21.2011
Cellceutix Signs Lab Services Research Support Agreement With Dana Farber/Partners CancerCare, Inc. 08.01.2011
With Contracts and IND Application in Hand, Cellceutix Nears Clinical Trials for New Cancer Drug 07.19.2011
Cellceutix Receives Notice of Acceptance for Phase 1 Clinical Trial 06.27.2011
Cellceutix Provides Updates on Kevetrin(TM), Cellceutix's Novel Anti-Cancer Therapy 06.20.2011
Cellceutix's Kevetrin(TM) Slows Pancreatic Cancer Tumor Growth by 94%; Protocol Towards Clinical Trials Nearing End Cellceutixs KevetrinSlows Pancreatic Cancer Tumor Growth by 94 percent - Protocol Towards Clinical Trials Nearing End 06.06.2011
Vendor Showcases Kevetrin(TM), Cellceutix's Anti-Cancer Drug at American Society for Mass Spectrometry Meeting 05.23.2011
Cellceutix CEO States "Full Speed Ahead" 05.16.2011
Cellceutix Announces Kevetrin™ in Combination with Radiation Delayed Tumor Growth by Twofold in Head and Neck Cancer Study 05.09.2011
Cellceutix Forwards Cancer Drug Study Protocol to Clinical Site 05.03.2011
Insight Into Cellceutix Corporation's Breakthrough Cancer Compound 04.25.2011
Cellceutix Cancer Drug Trumps Competitors - Kevetrin(TM) Stands Out in Its Mechanism of Action by Activating Both Transcription-Dependent and Transcription-Independent Pathways to Promote Apoptosis in a Non-Genotoxic Manner and Targets Both Mutated and Wild Type p53 04.18.2011
Cellceutix CEO, Leo Ehrlich, Conducts Interview with "Biotech Stock Trader"; Dr. Paul Ginsberg, (Renowned Patent Attorney) Joins Cellceutix Advisory Board 04.11.2011
Cellceutix Poster Presentation on its p53 Cancer Breakthrough Attracts Wide Interest at 102nd AACR Meeting 03.31.2011
Cellceutix Cancer Drug, Kevetrin, Shows Increased Levels of p21; Biomarker for Cancer Trials 03.28.2011
Cellceutix Announces that it has Signed Confidential Disclosure Agreement for its Autism Drug with Large Pharmaceutical Company 03.24.2011
Cellceutix Anti-Cancer Breakthrough Selected for Poster Presentation at American Association for Cancer Research (AACR) 03.14.2011
Cellceutix Reports Production of Its Anti-Cancer Drug Kevetrin Has Begun 03.09.2011
Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 03.07.2011
Cellceutix Discovers Drug Activates "Guardian Angel p53" in Fight Against Leukemia. 03.02.2011
Cellceutix Cancer Drug Kevetrin Shows No Genotoxicity in Study 02.28.2011
Cellceutix Makes Breakthrough in Cancer Research by Activating p53, the "Guardian Angel of the Human Genome" 02.14.2011
Cellceutix Announces Settlement With Former CEO 11.09.2010
Cellceutix Announces Departure of George W. Evans as CEO 11.04.2010
Cellceutix Receives Federal Grants for Each of Its Active Research Programs; Total Exceeds $730,000 10.28.2010
Cellceutix Nearing Completion of Toxicity Studies for Its Cancer Compound for the Treatment of Resistant Lung and Breast Cancers 09.28.2010
Cellceutix Nearing Completion of Toxicity Studies for Its Cancer Compound for the Treatment of Resistant Lung and Breast Cancers 08.24.2010
Cellceutix Closing in on Human Trials with Kevetrin(TM) for Drug-Resistant Cancers as the Company Reports Progress on Toxicity Studies 07.26.2010
Cellceutix Corporation Selects Destum Partners to Partner Psoriasis Compound 07.07.2010
Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Required by FDA Prior to Filing Investigational New Drug (IND) Application 06.23.2010
Cellceutix Autism Research Demonstrates Increase in Serotonin Levels in Three Areas of the Brain 06.21.2010
Kevetrin Demonstrates Significant Results in the Treatment of Multi-Drug Resistant Cancer Cells 06.14.2010
New Autism Drug Research by Cellceutix on Compound KM-391 Results in Significant Behavioral Changes; Chief Scientific Officer Sees Potential for Company to Emerge as Industry Leader as Pharmas Strive for Revolutionary Autism Treatments 06.07.2010
Cellceutix Responds to Public Support by Expediting Autism Studies; Completes Two Required Safety Pharmacology Studies for Its Cancer Compound 06.03.2010
Cellceutix CFO Discusses Autism Drug, Kevetrin™ and Company Progressions with CEOCFO Interviews and News 05.28.2010
Cellceutix Signs Agreements for Kevetrin(TM) Phase 1 Support-Company Continues to Advance Kevetrin Toward Human Studies Targeting Drug Resistant Cancers 05.18.2010
Cellceutix Files Foreign Patent Application in PCT and Other Key Countries for Its Flagship Cancer Compound 05.13.2010
Recent Announcements Suggest Cellceutix Is Well Positioned With Autism Compound; Pfizer and Novartis Announcements Indicate Interest in Autism by Major Companies 04.21.2010
Cellceutix Presents Poster Session at AACR; Important New Data on Kevetrin(TM) in Resistant Lung Cancer Model Show Dose Response; No Tumor Cell Resistance With Second Cycle 04.13.2010
Cellceutix at AACR 04.12.2010
Cellceutix Ceo Appears On ‘Stu Taylor On Business’: Cancer And Autism Compounds Are Discussed 03.29.2010
Cellceutix Announces Positive Results With Autism Compound, KM-391 Showing Significant Improvements On Key Parameters In Animal Studies 03.22.2010
Cellceutix Signs Agreement for Kevetrin(TM) Formulation With Formatech 03.15.2010
Cellceutix Abstract Accepted by AACR 02.18.2010
Cellceutix Completes Successful Pre-IND Meeting With FDA for Cancer Drug 11.02.2009
Cellceutix Signs Agreement for Kevetrin(TM) Safety Studies with Toxikon Corporation 10.13.2009
Dr. Menon Selected For Expert Panel 10.06.2009
Cellceutix Compound Shows Significant Effect On Psoriasis 09.21.2009
Cellceutix's Kevetrin™ Demonstrates Significant Delay of Tumor Growth in Drug Resistant Breast Cancer 08.26.2009
Cellceutix Announces Acquisition of New Compound With High Blood Pressure Lowering Properties 08.18.2009
Cellceutix Signs Manufacturing Agreement for Kevetrin™ Active Pharmaceutical Ingredient 07.15.2009
Cellceutix Announces Dr. Samuel Danishefsky Joins Its Scientific Advisory Board 07.13.2009
Kevetrin™ Animal Model Testing Success Against Multi-Drug Resistant Lung Cancer 06.30.2009
Cellceutix Announces Dr. Emil Frei to be On Its Scientific Advisory Board Through June 30, 2010 05.29.2008
Cellceutix cancer compound: Crunching the numbers
Latest News
Syracuse basketball coach Jim Boeheim keeps working for cancer breakthrough 05.02.2012
Cellceutix CEO Leo Ehrlich Interviewed by TheStreetBeat.com 05.01.2012
CTIX and CTIC: A Demonstration in Biotech Stock Ticker Confusion 11.22.2012
Cellceutix Eyeing A $5B Annual Market With Potential Cancer Research Breakthrough 11.15.2011
Guru Focus : Interview With CEO Of Cellceutix Corporation: Leo Ehrlich 11.08.2011
Cellceutix Matriculates to Harvard 04.15.2011
Cellceutix (OTCQB: CTIX) Management Outlines Enormous Potential in Exclusive Interview with BiotechStockTrader.com 06.03.2010
CEOCFO Interviews: Interview with Leo Ehrlich, CFO. 04.12.2010
Listen to: Stu Taylor on Business, April 10, 2010 show 04.07.2010
The Salem News: Autism drug tested on rats 10.19.2009
Startup pharma company runs a tight ship on path to crucial human testing 10.06.2009
Interview with George Evans, Cellceutix's CEO, at SmallCapVoice.com 10.06.2009
Breast Cancer Awareness Month Draws Investors Too 09.11.2009
Girindus America will manufacture the API for Cellceutix Corp's Kevetrin product 09.09.2009
IFCR in pact for collaborative research 08.25.2009
Cellceutix Corporation has acquired the rights to the blood pressure compound KM 732 08.20.2009
Cellceutix signs agreement with Girindus America 05.21.2009
Cellceutix Files Patent Application For Its Cancer Compound 05.14.2008
Cellceutix Obtains Initial Funding to Advance Its Head and Neck Cancer Drug